CL2021002407A1 - Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias - Google Patents

Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias

Info

Publication number
CL2021002407A1
CL2021002407A1 CL2021002407A CL2021002407A CL2021002407A1 CL 2021002407 A1 CL2021002407 A1 CL 2021002407A1 CL 2021002407 A CL2021002407 A CL 2021002407A CL 2021002407 A CL2021002407 A CL 2021002407A CL 2021002407 A1 CL2021002407 A1 CL 2021002407A1
Authority
CL
Chile
Prior art keywords
interleukin
variants
receptor
il2r
amino acid
Prior art date
Application number
CL2021002407A
Other languages
English (en)
Inventor
Ugur Sahin
Sina Fellermeier-Kopf
Alexander Muik
Matthias Birtel
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of CL2021002407A1 publication Critical patent/CL2021002407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a variantes de la subunidad alfa de receptor de interleucina-2 (IL2R) e interleucina-2 (IL2). En una forma de realización, las variantes de IL2 descritas en la presente tienen sustituciones de aminoácidos en la región de IL2 que pone en contacto la subunidad alfa (α) del complejo del receptor de IL2 heterotrimérico, IL2Rαβγ, que reduce su capacidad para enlazarse y activar el complejo receptor heterotrimérico. Por otro lado, las correspondientes variantes de IL2Rα descritas en la presente tienen sustituciones de aminoácidos que compensan la capacidad tan reducida de variantes IL2 para enlazarse a y activar IL2Rαβγ, preferiblemente en residuos de aminoácidos en contacto con residuos de aminoácidos de IL2 que están sustituidos en las variantes de IL2 descritas en la presente.
CL2021002407A 2019-03-18 2021-09-15 Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias CL2021002407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2019056719 2019-03-18

Publications (1)

Publication Number Publication Date
CL2021002407A1 true CL2021002407A1 (es) 2022-05-27

Family

ID=69780223

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002407A CL2021002407A1 (es) 2019-03-18 2021-09-15 Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias

Country Status (15)

Country Link
US (1) US20220177544A1 (es)
EP (1) EP3941935A1 (es)
JP (1) JP2022525921A (es)
KR (1) KR20210143759A (es)
CN (1) CN113874389A (es)
AU (1) AU2020242254A1 (es)
BR (1) BR112021016962A2 (es)
CA (1) CA3133414A1 (es)
CL (1) CL2021002407A1 (es)
CO (1) CO2021013687A2 (es)
CU (1) CU20210078A7 (es)
IL (1) IL285584A (es)
MX (1) MX2021011258A (es)
SG (1) SG11202108857SA (es)
WO (1) WO2020187848A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20070178082A1 (en) 2002-11-08 2007-08-02 Ablynx N.V. Stabilized single domain antibodies
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EA201000979A1 (ru) 2007-12-27 2011-02-28 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
PT2274331E (pt) 2008-05-02 2014-02-27 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
KR20130056871A (ko) 2010-04-13 2013-05-30 브리스톨-마이어스 스큅 컴퍼니 Ｐｃｓｋ９에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
AU2012311451B2 (en) 2011-09-23 2017-08-10 Universitat Stuttgart Serum half-life extension using immunoglobulin binding domains
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
MA40721A (fr) * 2014-08-06 2017-06-13 The Univ Of Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SG11202013044PA (en) * 2018-07-24 2021-02-25 Biontech Rna Pharmaceuticals Gmbh Il2 agonists

Also Published As

Publication number Publication date
MX2021011258A (es) 2021-12-10
CA3133414A1 (en) 2020-09-24
CU20210078A7 (es) 2022-04-07
BR112021016962A2 (pt) 2021-11-23
WO2020187848A1 (en) 2020-09-24
CO2021013687A2 (es) 2021-10-29
AU2020242254A1 (en) 2020-09-24
JP2022525921A (ja) 2022-05-20
CN113874389A (zh) 2021-12-31
SG11202108857SA (en) 2021-09-29
KR20210143759A (ko) 2021-11-29
AU2020242254A9 (en) 2021-10-28
US20220177544A1 (en) 2022-06-09
IL285584A (en) 2021-09-30
EP3941935A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
CO2020009625A2 (es) Inhibidor de fap
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
ES2531288T3 (es) Proteína de fusión anticancerígena
MD3242887T2 (ro) Compuși co-agonişti ai GIP și GLP-1
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
CR20160049A (es) Bioconjugados de polipéptidos de apelina sintética
CL2023001417A1 (es) Composiciones de inhibidores peptídicos del receptor de interleucina - 23.
AR091218A1 (es) Agente terapeutico o agente profilactico para los trastornos cognitivos
ES2380951T3 (es) Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
CL2021002407A1 (es) Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias
PE20200697A1 (es) Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
WO2018053180A3 (en) Proximity-based sortase-mediated protein purification and ligation
GB202015333D0 (en) Contact levitation triggering mechanisms for use with switching devices incorporating pyrotechnic features
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
BR112012006579A2 (pt) agonistas de npr-b.
CU20190078A7 (es) Péptidos útiles en el tratamiento de diabetes
MX2017006748A (es) Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
CL2020003034A1 (es) Agonistas de tlr7
BR112018012844A2 (pt) polipeptídeos para inibir a ativação de complemento
JP1747428S (ja) 靴
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
ECSP15014925A (es) Compuestos para tratar el bloqueo de remielinizacion en enfermedades asociadas con la expresion de la proteina de envoltura herv-w
BRPI1010215A8 (pt) dispositivo e método
CO2021010392A2 (es) Dispositivo móvil para el tratamiento de la picazón con una interfaz